Mantle Cell Lymphoma News and Research

RSS

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Researchers develop interference therapies to knock down gene that drives MCL

Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.

From Integrated DNA Technologies 11 Oct 2012

Sarawak Biodiversity Centre in Malaysia, OSU to develop and commercialize anticancer agent

The Ohio State University has signed an agreement with the Sarawak Biodiversity Centre in Malaysia to collaborate on the further development and commercialization of a promising anticancer agent derived from a tropical tree that grows on the island of Borneo.

25 Sep 2012

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.

30 Jul 2012

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Senesco Technologies, Inc. reported today that it was informed on July 26th that the U.S. Food and Drug Administration has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma and diffuse large B-cell lymphoma.

30 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

23 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

19 May 2012

Lenalidomide and SNS01-T combination effective against multiple myeloma

Senesco Technologies, Inc. announced today that a high level of tumor eradication in a mouse model of human multiple myeloma was achieved with a combination of SNS01-T and lenalidomide.

2 May 2012

Scientists discover why rapamycin causes diabetic-like symptoms in patients

Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.

4 Apr 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

FLT-PET imaging can effectively detect mantle cell lymphoma

Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method for imaging a form of Non-Hodgkin's disease called mantle cell lymphoma, a relatively rare and devastating blood cancer.

22 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

When the American Society of Hematology convenes its 53rd Annual Meeting and Exposition on Dec. 10-13 in San Diego, Calif., researchers from Moffitt Cancer Center will break a new record for Moffitt participants with one plenary presentation, 16 oral presentations and more than 50 poster presentations on new research results in a variety of meeting programs that focus on blood cancer basic science and clinical applications, including bone marrow transplantation and clinical trials results.

5 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

First-ever Mantle Cell Lymphoma Symposium to be held on Nov. 12

The Lymphoma Division of the John Theurer Cancer Center at Hackensack University Medical Center with the participation from the Facebook groups "Hope for Lymphoma" and "Our MCL Family," will host its first-ever Mantle Cell Lymphoma Symposium on Saturday, November 12 from 8:30am - 3:45pm.

8 Nov 2011